From tolerance to resistance: adaptive pathways of enterobacterales persistence in the GUT under antibiotic pressure

Active Grant Awarded

Award ID
R01AI201613
Recipient
Awarding agency
Obligated
$741,051

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 8% complete
Place of performance
Chapel Hill, NC 27599, USA

Award details come from USAspending.gov.

About this award

The National Institutes of Health's National Institute of Allergy and Infectious Diseases, within the Department of Health and Human Services, awarded Grant R01AI201613 to University of North Carolina at Chapel Hill, Office of Sponsored Research, obligating $741,051 on June 30, 2026, under Assistance Listing 93.855, Allergy and Infectious Diseases Research. The award funds research on whether antibiotic tolerance, the ability of bacteria to survive lethal antibiotic concentrations without a change in minimum inhibitory concentration, drives persistence of gut Enterobacterales in hematopoietic cell transplant patients. Aim 1 selectively cultures E. coli and K. pneumoniae from stool samples and quantifies tolerance through high-throughput TD test screening and standardized time-kill assays with multiple antibiotics. Aim 2 identifies genetic determinants of tolerance by sequencing paired stool metagenomes and isolates. The work spans two large hematopoietic cell transplant cohorts. The period of performance runs through June 30, 2031, with performance at Chapel Hill, North Carolina 27599. Sub-award R01AI201613-5138745, dated September 19, 2026, runs to University of North Carolina at Charlotte, which provides data analysis and statistical modeling of all microbial sequence data.

Description

Abstract
And abstract hematopoietic stem cell transplantation (HCT) cures hematologic malignancies, but infection-related mortality remains high, with bloodstream infections (BSIS) accounting for up to one-quarter of deaths in the first year. Enterobacterales translocation from the GUT is the primary source of these infections. While antibiotic (ABX) prophylaxis reduces BSI risk, incomplete clearance of potential pathogens in the GUT allows susceptible strains to persist and acquire AMR under ongoing pressure, further limiting ABX effectiveness. GUT enterobacterales often persist despite in vitro susceptibility, suggesting a survival mechanism beyond resistance that remains underexplored. We hypothesize that antibiotic tolerance-the ability of bacteria to survive lethal antibiotic concentrations without a change in minimum inhibitory concentration-is the key driver of enterobacterales persistence in the GUT and a precursor to AMR. Preliminary data show that GUT-resident E. Coli and K. Pneumoniae persist in almost two- thirds of HCT patients despite antibiotic use and that tolerance levels rise during ABX and decrease after withdrawal. We find that recurrent mutations in tolerance loci such as rela, hipa, and ptsi occur during ABX treatment, and that tolerant strains acquire resistance more rapidly under antibiotic pressure in vitro. To test this hypothesis, we will combine culture-based and genomic approaches across two large HCT cohorts. In aim 1 we will selectively culture E. Coli and K. Pneumoniae from stool samples and quantify tolerance using high-throughput screening (TD test) and standardized time-kill assays with multiple antibiotics to measure both isolate- and population-level survival. In aim 2 we will identify genetic determinants of tolerance by sequencing paired stool metagenomes and isolates, tracking the emergence of single-nucleotide variants in known tolerance genes, and performing bacterial genome-wide association studies (GWAS) to discover novel loci. Candidate genes will be validated through plasmid complementation and functional assays. In aim 3 we will link tolerance to clinical outcomes by integrating stool and bloodstream isolate sequencing with longitudinal antibiotic exposure data in order to determine whether tolerant strains predict BSIS and accelerate acquisition of phenotypic or genotypic AMR. This project will be the first to investigate the reservoir of antibiotic tolerance in the human GUT microbiome of immunocompromised patients. Using complementary microbiology and isolate/stool genomics, we will directly link in vivo tolerance phenotypes to genetic mechanisms and clinical outcomes. Establishing how tolerance enables enterobacterales to persist in the GUT, seed bloodstream infections, and accelerate resistance in HCT patients likely has impact for other vulnerable groups. By identifying tolerance as a critical determinant of infection and AMR risk this work will identify novel strategies in overcoming tolerance to improve pathogen clearance, limit multidrug-resistant transmission, and reduce infection-related mortality in immunocompromised patients.

Subawards

Subrecipient Amount Awarded
University Of North Carolina At Charlotte University of North Carolina-Charlotte investigator will provide data analysis and statistical modeling of all microbial sequence data. $90,674

Quick answers

Who received award R01AI201613?

R01AI201613 was awarded to University Of North Carolina At Chapel Hill by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 30, 2026.

How much is award R01AI201613 worth?

$741,051 has been obligated on R01AI201613.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award